MedTrace Logo

Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma

NCT07598955 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-05-20

No results posted yet for this study

Summary

This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma. Participants undergo centralized tumor antigen assessment (CD30, CD5, and mesothelin). Based on the dominant and clinically actionable antigen expression profile, each participant is assigned to one of three parallel cohorts (CD30-CAR-NK, CD5-CAR-NK, or mesothelin-CAR-NK). All cohorts use the same lymphodepleting conditioning regimen followed by CAR-NK infusion(s).

Conditions

  • B2 Thymoma
  • Thymic Carcinoma

Interventions

DRUG

Cyclophosphamide

lymphodepletion

DRUG

Fludarabine

lymphodepletion

BIOLOGICAL

EB-CAR30-NK

CD30-targeted allogeneic CAR-NK cells

BIOLOGICAL

EB-CAR5-NK

CD5-targeted allogeneic CAR-NK cells

BIOLOGICAL

EB-CARMSLN-NK

Mesothelin-targeted allogeneic CAR-NK cells

DRUG

Rimiducid (AP1903)

ctivate the iCasp9 safety switch if clinically indicated

Sponsors & Collaborators

  • Beijing Biotech

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2027-06-14
Completion
2028-04-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07598955 on ClinicalTrials.gov